65
Participants
Start Date
December 13, 2012
Primary Completion Date
January 31, 2020
Study Completion Date
July 31, 2024
Everolimus
Everolimus tablet will be taken daily by mouth with water. All participants will be given a dose of 5 mg/m2/dose daily.
The Children's Hospital Of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Johns Hopkins University, Baltimore
University of Florida, Gainesville
St. Jude Children's Research Hospital, Memphis
Nationwide Children's Hospital, Columbus
Children's Hospitals and Clinics of Minneapolis, Minneapolis
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
St. Louis Children's Hospital, Washington University, St Louis
University of Utah, Salt Lake City
Children's Hospital Los Angeles, Los Angeles
University of California, Los Angeles, Los Angeles
University of California, San Diego Rady Children's Hospital, San Diego
University of California, San Francisco, San Francisco
Children's Hospital Oakland, Oakland
Oregon Health & Science University, Portland
University of Washington, Seattle, Seattle
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Pacific Pediatric Neuro-Oncology Consortium
OTHER
The Pediatric Low Grade Astrocytoma (PLGA) Foundation
OTHER
University of California, San Francisco
OTHER